SG11201407703QA - Methanethione compounds having antiviral activity - Google Patents
Methanethione compounds having antiviral activityInfo
- Publication number
- SG11201407703QA SG11201407703QA SG11201407703QA SG11201407703QA SG11201407703QA SG 11201407703Q A SG11201407703Q A SG 11201407703QA SG 11201407703Q A SG11201407703Q A SG 11201407703QA SG 11201407703Q A SG11201407703Q A SG 11201407703QA SG 11201407703Q A SG11201407703Q A SG 11201407703QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- compound
- formula
- stockholm
- methanethione
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261648700P | 2012-05-18 | 2012-05-18 | |
US201261659516P | 2012-06-14 | 2012-06-14 | |
US201261666286P | 2012-06-29 | 2012-06-29 | |
US201361774991P | 2013-03-08 | 2013-03-08 | |
PCT/EP2013/060266 WO2013171334A1 (en) | 2012-05-18 | 2013-05-17 | Methanethione compounds having antiviral activity |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201407703QA true SG11201407703QA (en) | 2015-01-29 |
Family
ID=48444409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201407703QA SG11201407703QA (en) | 2012-05-18 | 2013-05-17 | Methanethione compounds having antiviral activity |
Country Status (21)
Country | Link |
---|---|
US (1) | US9359310B2 (sl) |
EP (1) | EP2870141B1 (sl) |
JP (2) | JP6484168B2 (sl) |
KR (1) | KR102092207B1 (sl) |
CN (1) | CN104540810B (sl) |
AU (1) | AU2013261735B2 (sl) |
BR (1) | BR112014028632B1 (sl) |
CA (1) | CA2879816C (sl) |
CL (1) | CL2014003116A1 (sl) |
DK (1) | DK2870141T3 (sl) |
EA (1) | EA029044B1 (sl) |
ES (1) | ES2657942T3 (sl) |
HK (1) | HK1210165A1 (sl) |
IL (1) | IL235742A0 (sl) |
IN (1) | IN2014DN10658A (sl) |
MX (1) | MX356846B (sl) |
MY (1) | MY169094A (sl) |
NZ (1) | NZ702073A (sl) |
SG (1) | SG11201407703QA (sl) |
WO (1) | WO2013171334A1 (sl) |
ZA (1) | ZA201409220B (sl) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013171334A1 (en) * | 2012-05-18 | 2013-11-21 | Vironova Ab | Methanethione compounds having antiviral activity |
CN107056762B (zh) * | 2016-12-22 | 2020-08-28 | 四川百利药业有限责任公司 | 一种用作抗流感病毒的双羰基类似物 |
WO2021204923A1 (en) | 2020-04-09 | 2021-10-14 | Vironova Medical Ab | Antiviral agents |
WO2021204924A1 (en) | 2020-04-09 | 2021-10-14 | Vironova Medical Ab | Compounds for use in the treatment of hypercytokinemia |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6642390B2 (en) | 2001-07-11 | 2003-11-04 | Lexicon Pharmaceuticals, Inc. | One step synthesis of 1,2,3-triazole carboxylic acids |
AU2004218260A1 (en) * | 2003-01-28 | 2004-09-16 | Aventis Pharma S.A. | N-aryl heteroaromatic products, compositions containing same and use thereof |
WO2009131957A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising oxadiazole derivatives |
EP2462138B1 (en) | 2009-08-05 | 2014-09-24 | Versitech Limited | Antiviral compounds and methods of making |
JP2013542201A (ja) * | 2010-09-28 | 2013-11-21 | ブリストル−マイヤーズ スクイブ カンパニー | 広域スペクトルのインフルエンザ抗ウイルス剤としての置換されたヘテロアリール基を有する新規ピペラジン類似体 |
EP2484655A1 (en) | 2011-02-04 | 2012-08-08 | Vironova AB | A thionation process and a thionating agent |
WO2013171334A1 (en) * | 2012-05-18 | 2013-11-21 | Vironova Ab | Methanethione compounds having antiviral activity |
JP6762767B2 (ja) * | 2016-06-01 | 2020-09-30 | キヤノン株式会社 | 撮像素子、撮像装置、および撮像信号処理方法 |
-
2013
- 2013-05-17 WO PCT/EP2013/060266 patent/WO2013171334A1/en active Application Filing
- 2013-05-17 KR KR1020147035090A patent/KR102092207B1/ko active IP Right Grant
- 2013-05-17 ES ES13722781.5T patent/ES2657942T3/es active Active
- 2013-05-17 BR BR112014028632A patent/BR112014028632B1/pt not_active IP Right Cessation
- 2013-05-17 CA CA2879816A patent/CA2879816C/en active Active
- 2013-05-17 JP JP2015512081A patent/JP6484168B2/ja active Active
- 2013-05-17 AU AU2013261735A patent/AU2013261735B2/en active Active
- 2013-05-17 MX MX2014014007A patent/MX356846B/es active IP Right Grant
- 2013-05-17 SG SG11201407703QA patent/SG11201407703QA/en unknown
- 2013-05-17 MY MYPI2014003200A patent/MY169094A/en unknown
- 2013-05-17 EP EP13722781.5A patent/EP2870141B1/en active Active
- 2013-05-17 IN IN10658DEN2014 patent/IN2014DN10658A/en unknown
- 2013-05-17 EA EA201401277A patent/EA029044B1/ru not_active IP Right Cessation
- 2013-05-17 DK DK13722781.5T patent/DK2870141T3/da active
- 2013-05-17 NZ NZ702073A patent/NZ702073A/en unknown
- 2013-05-17 US US14/401,545 patent/US9359310B2/en not_active Expired - Fee Related
- 2013-05-17 CN CN201380038170.2A patent/CN104540810B/zh active Active
-
2014
- 2014-11-17 CL CL2014003116A patent/CL2014003116A1/es unknown
- 2014-11-17 IL IL235742A patent/IL235742A0/en active IP Right Grant
- 2014-12-15 ZA ZA2014/09220A patent/ZA201409220B/en unknown
-
2015
- 2015-11-09 HK HK15110998.4A patent/HK1210165A1/xx unknown
-
2017
- 2017-11-09 JP JP2017216649A patent/JP2018065817A/ja not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
KR102092207B1 (ko) | 2020-03-23 |
BR112014028632A2 (pt) | 2017-06-27 |
AU2013261735A1 (en) | 2015-01-22 |
HK1210165A1 (en) | 2016-04-15 |
NZ702073A (en) | 2017-07-28 |
MX356846B (es) | 2018-06-18 |
DK2870141T3 (da) | 2018-01-29 |
EP2870141B1 (en) | 2017-11-22 |
BR112014028632A8 (pt) | 2018-04-03 |
MY169094A (en) | 2019-02-18 |
EA201401277A1 (ru) | 2015-04-30 |
KR20150012289A (ko) | 2015-02-03 |
IN2014DN10658A (sl) | 2015-08-28 |
CN104540810A (zh) | 2015-04-22 |
JP2018065817A (ja) | 2018-04-26 |
US9359310B2 (en) | 2016-06-07 |
EA029044B1 (ru) | 2018-02-28 |
EP2870141A1 (en) | 2015-05-13 |
CA2879816C (en) | 2020-07-07 |
ZA201409220B (en) | 2016-08-31 |
US20150133468A1 (en) | 2015-05-14 |
JP2015517516A (ja) | 2015-06-22 |
ES2657942T3 (es) | 2018-03-07 |
MX2014014007A (es) | 2015-05-11 |
WO2013171334A1 (en) | 2013-11-21 |
JP6484168B2 (ja) | 2019-03-13 |
CN104540810B (zh) | 2017-01-18 |
IL235742A0 (en) | 2015-02-01 |
AU2013261735B2 (en) | 2017-07-20 |
CL2014003116A1 (es) | 2015-08-07 |
BR112014028632B1 (pt) | 2020-01-28 |
CA2879816A1 (en) | 2013-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201407228PA (en) | N-aryltriazole compounds as lpar antagonists | |
SG11201407037UA (en) | Catechol o-methyltransferase activity inhibiting compounds | |
SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
SG11201408094YA (en) | Neprilysin inhibitors | |
SG11201407220YA (en) | N-alkyltriazole compounds as lpar antagonists | |
SG11201407200TA (en) | Liquid formulation | |
SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
SG11201408659UA (en) | Load carrying platform shuttle | |
SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
SG11201408303WA (en) | Adhesive compositions of propylene-based and ethylene-based polymers | |
SG11201408539UA (en) | Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof | |
SG11201408237YA (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
SG11201408629QA (en) | Dimethyl-benzoic acid compounds | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
SG11201407189XA (en) | C-17 bicyclic amines of triterpenoids with hiv maturation inhibitory activity | |
SG11201407536UA (en) | Topical pharmaceutical compositions comprising terbinafine and urea | |
SG11201407229UA (en) | Substituted pyrazole compounds as lpar antagonists | |
SG11201407345QA (en) | Pyrazole compounds as sglt1 inhibitors | |
SG11201406787TA (en) | Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies | |
SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors |